Results 1 to 10 of about 583,778 (211)
Purinergic signaling: Diverse effects and therapeutic potential in cancer
Frontiers in Oncology, 2023 Regardless of improved biological insights and therapeutic advances, cancer is consuming multiple lives worldwide. Cancer is a complex disease with diverse cellular, metabolic, and physiological parameters as its hallmarks.
Jasmeet Kaur, Sanchit Dora
doaj +1 more source
Purinergic Signaling in Mast Cell Degranulation and Asthma
Frontiers in Pharmacology, 2017 Mast cells are responsible for the majority of allergic conditions. It was originally thought that almost all allergic events were mediated directly only via the high-affinity immunoglobulin E receptors.
Zhan-Guo Gao, Kenneth A. Jacobson
doaj +1 more source
Mediators of Inflammation, 2015 Purinergic mediators such as adenosine 5′-triphosphate (ATP) are released into the extracellular compartment from damaged tissues and activated immune cells. They are then recognized by multiple purinergic P2X and P2Y receptors.
Yosuke Kurashima +2 more
doaj +1 more source
Purine and purinergic receptors
Brain and Neuroscience Advances, 2018 Adenosine 5′-triphosphate acts as an extracellular signalling molecule (purinergic signalling), as well as an intracellular energy source. Adenosine 5′-triphosphate receptors have been cloned and characterised. P1 receptors are selective for adenosine, a
Geoffrey Burnstock
doaj +1 more source
Purinergic Receptors in Adipose Tissue As Potential Targets in Metabolic Disorders
Frontiers in Pharmacology, 2017 Extracellular nucleosides and nucleotides, such as adenosine and adenosine triphosphate (ATP), are involved in many physiological and pathological processes in adipose tissue (AT).
Marco Tozzi, Ivana Novak
doaj +1 more source
Purinergic signaling in the modulation of redox biology
Redox Biology, 2021 Purinergic signaling is a cell communication pathway mediated by extracellular nucleotides and nucleosides. Tri- and diphosphonucleotides are released in physiological and pathological circumstances activating purinergic type 2 receptors (P2 receptors ...
Luiz Eduardo Baggio Savio +4 more
doaj +1 more source
P2Y6 receptor potentiates pro-inflammatory responses in macrophages and exhibits differential roles in atherosclerotic lesion development. [PDF]
PLoS ONE, 2014 BACKGROUND: P2Y(6), a purinergic receptor for UDP, is enriched in atherosclerotic lesions and is implicated in pro-inflammatory responses of key vascular cell types and macrophages. Evidence for its involvement in atherogenesis, however, has been lacking.
Ricardo A Garcia +17 more
doaj +1 more source
The adenosinergic machinery in cancer: In-tandem insights from basic mechanisms to therapy
Frontiers in Immunology, 2023 Extracellular adenosine (eADO) signaling has emerged as an increasingly important regulator of immune responses, including tumor immunity. eADO is mainly produced from extracellular ATP (eATP) hydrolysis.
Chifei Kang +12 more
doaj +1 more source
Purinergic signaling in schistosomal infection
Biomedical Journal, 2016 Human schistosomiasis is a chronic inflammatory disease caused by blood fluke worms belonging to the genus Schistosoma. Health metrics indicate that the disease is related to an elevated number of years lost-to-disability and years lost-to-life ...
Claudia Lucia Martins Silva
doaj +1 more source
Folia Neuropathologica, 2022 Purinergic signalling is involved in the control of several processes related to brain development, such as neurogenesis and gliogenesis, migration and differentiation of neuronal precursors, synaptogenesis and synaptic elimination to achieve a fully ...
Lidia Babiec +2 more
doaj +1 more source